Compare AAT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | NBTX |
|---|---|---|
| Founded | 1967 | 2003 |
| Country | United States | France |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2010 | 2018 |
| Metric | AAT | NBTX |
|---|---|---|
| Price | $25.31 | $37.81 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $19.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 455.3K | 67.4K |
| Earning Date | 04-28-2026 | 03-31-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | $58.17 |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $315.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $4.79 |
| 52 Week High | $25.34 | $57.14 |
| Indicator | AAT | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.84 | 51.60 |
| Support Level | $18.23 | $30.15 |
| Resistance Level | N/A | $38.29 |
| Average True Range (ATR) | 0.49 | 2.46 |
| MACD | -0.02 | 0.45 |
| Stochastic Oscillator | 88.95 | 67.69 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.